Literature DB >> 11757183

[Radiotherapy of early stage Dupuytren disease. Long-term results after a median follow-up period of 10 years].

B Adamietz1, L Keilholz, J Grünert, R Sauer.   

Abstract

PURPOSE: In early stage Dupuytren's contracture radiotherapy was applied to prevent disease progression. Long-term results and late toxicity of this treatment were evaluated in a retrospective analysis. PATIENTS AND METHODS: Between 1982 and 1994, 99 patients (176 hands) received orthovoltage radiotherapy, which consisted of two courses with 5 x 3 Gy (total dose: 30 Gy, daily fractionated; 120 kV, 4 mm Al), separated by a 6 to 8-week pause. The Dupuytren's contracture was staged according to the classification of Tubiana et al. The long-term outcome was analyzed at last follow-up between July and November 1999. The median follow-up was 10 years (range 7-18 years). Late toxicity was assessed using the LENT-SOMA criteria.
RESULTS: In Stage N 84% and Stage N/I 67% of cases remained stable. 65% of the cases in Stage I and 83% in Stage II showed progressive nodules and cords. In case of progression we saw no complications after a second radiotherapy or salvage operation.
CONCLUSION: Radiotherapy effectively prevents disease progression for early stage Dupuytren's contracture (Stage N, N/I). Moreover, in case of disease progression despite radiotherapy salvage surgery is still feasible.

Entities:  

Mesh:

Year:  2001        PMID: 11757183     DOI: 10.1007/pl00002371

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  8 in total

Review 1.  Management of Dupuytren's disease--clear advice for an elusive condition.

Authors:  A Bayat; D A McGrouther
Journal:  Ann R Coll Surg Engl       Date:  2006-01       Impact factor: 1.891

2.  DEGRO guidelines for the radiotherapy of non-malignant disorders : part III: hyperproliferative disorders.

Authors:  M Heinrich Seegenschmiedt; Oliver Micke; Marcus Niewald; Ralph Mücke; Hans Theodor Eich; Jan Kriz; Reinhard Heyd
Journal:  Strahlenther Onkol       Date:  2015-03-10       Impact factor: 3.621

3.  Radiotherapy in early-stage Dupuytren's contracture. Long-term results after 13 years.

Authors:  Nicolas Betz; Oliver J Ott; Boris Adamietz; Rolf Sauer; Rainer Fietkau; Ludwig Keilholz
Journal:  Strahlenther Onkol       Date:  2010-01-28       Impact factor: 3.621

4.  Feasibility of aponeurectomy in combination with perioperative 192Ir high dose rate brachytherapy for Dupuytren's disease.

Authors:  I Frank Ciernik; Philipp Goldschmidt; Markus Wösle; Jochen Winter
Journal:  Strahlenther Onkol       Date:  2021-09-07       Impact factor: 3.621

5.  Radiation therapy for early stages of morbus Ledderhose.

Authors:  Reinhard Heyd; Anne Pia Dorn; Markus Herkströter; Claus Rödel; Marcus Müller-Schimpfle; Ingeborg Fraunholz
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

Review 6.  Radiotherapy for non-malignant disorders: state of the art and update of the evidence-based practice guidelines.

Authors:  M H Seegenschmiedt; O Micke; R Muecke
Journal:  Br J Radiol       Date:  2015-05-08       Impact factor: 3.039

Review 7.  Systematic review of non-surgical treatments for early dupuytren's disease.

Authors:  Catherine Ball; David Izadi; Liaquat Suleman Verjee; James Chan; Jagdeep Nanchahal
Journal:  BMC Musculoskelet Disord       Date:  2016-08-15       Impact factor: 2.362

8.  Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with an embedded dose response study.

Authors:  Jagdeep Nanchahal; Catherine Ball; Jennifer Swettenham; Susan Dutton; Vicki Barber; Joanna Black; Bethan Copsey; Melina Dritsaki; Peter Taylor; Alastair Gray; Marc Feldmann; Sarah Lamb
Journal:  Wellcome Open Res       Date:  2017-06-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.